New research reveals that individuals who stop using popular GLP-1 drugs like Mounjaro or Wegovy may regain lost weight far faster than those who end traditional lifestyle programs.
Research printed in a leading medical journal demonstrates that while overweight individuals frequently drop a large proportion of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying these treatments should be aware of the potential of fast weight regain when the medication concludes," warns researcher Dr. Susan Jebb.
This pace of recovery implies a return to original weight in about one and a half years.
Comparing Treatments
The research, which looked at dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with other pills.
The team point out that individuals who shed pounds through diet and exercise usually see a more gradual creep back—approximately 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Nutrition scientists propose the way of the jabs is key to understanding the heightened rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication means appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Condition?
The NHS recommend the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Professionals contend that, due to the significant potential of relapse, the therapy is often long-term.
This perspective is reinforced by pharmaceutical companies, who say that the results "emphasize the persistent nature of excess weight," similar to managing diseases like high blood pressure.
User Accounts
People who have come off the medication report a intense resurgence of hunger.
"It felt as if a trigger activating and I was suddenly ravenous," described an individual.
The struggle is compounded if users have not adopted sustainable dietary or behavioural changes during therapy.
Growing Interest
Figures indicate that millions of people in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Ultimately, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a magic fix and lasting health benefits hinges on integrated lifestyle management.
